Ad
LLY Quote Trading Chart Eli Lilly and Company
Quote | Eli Lilly and Company (NYSE:LLY)
| Last: | $803.58 |
|---|---|
| Change Percent: | 0.36% |
| Open: | $823.7 |
| Close: | $803.58 |
| High: | $823.7 |
| Low: | $801.28 |
| Volume: | 3,135,970 |
| Last Trade Date Time: | 12/09/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
LLY Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $803.58 | $823.7 | $803.58 | $823.7 | $801.28 | 3,135,970 | 12-09-2024 |
| $826.71 | $827.68 | $826.71 | $841 | $825.6901 | 3,047,127 | 12-06-2024 |
| $825.62 | $827.78 | $825.62 | $831.13 | $817.46 | 2,423,388 | 12-05-2024 |
| $829.84 | $828.1 | $829.84 | $846.4629 | $820.5 | 3,871,090 | 12-04-2024 |
| $813.33 | $802.93 | $813.33 | $817.13 | $801.61 | 2,782,067 | 12-03-2024 |
| $799.8 | $798.11 | $799.8 | $805.35 | $795.2201 | 2,895,629 | 12-02-2024 |
| $795.35 | $791.33 | $795.35 | $800.33 | $789.331 | 2,206,918 | 11-29-2024 |
| $788.19 | $788.12 | $788.19 | $794.83 | $780.3 | 2,714,656 | 11-28-2024 |
| $788.19 | $788.12 | $788.19 | $794.83 | $780.3 | 2,714,656 | 11-27-2024 |
| $789.32 | $785.2 | $789.32 | $807 | $773.95 | 6,622,610 | 11-26-2024 |
| $755 | $750 | $755 | $755 | $740.01 | 5,690,465 | 11-25-2024 |
| $748.01 | $757.05 | $748.01 | $761.2799 | $745.0812 | 4,015,450 | 11-22-2024 |
| $749.92 | $746.12 | $749.92 | $752.9999 | $735 | 4,143,204 | 11-21-2024 |
| $753.41 | $735.785 | $753.41 | $757.37 | $735.46 | 5,158,855 | 11-20-2024 |
| $729.73 | $716.31 | $729.73 | $730 | $712.42 | 5,832,480 | 11-19-2024 |
| $727.2 | $733.19 | $727.2 | $734 | $711.4001 | 9,154,351 | 11-18-2024 |
| $746.2 | $775.19 | $746.2 | $777.98 | $744.2 | 7,334,562 | 11-15-2024 |
| $786.23 | $809.19 | $786.23 | $809.19 | $783.51 | 3,998,847 | 11-14-2024 |
| $811.81 | $820.32 | $811.81 | $829.105 | $811.29 | 3,059,268 | 11-13-2024 |
| $818.86 | $830.2 | $818.86 | $833.99 | $810.7201 | 3,378,563 | 11-12-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting PR Newswire Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced ...
-
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase PR Newswire INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Today, the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share ...
-
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade PR Newswire Pro Football Hall of Famer Brian Dawkins joins the team to motivate those at risk for kidney disease to prioritize compl...